|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
NARATRIPTAN HYDROCHLORIDE
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
C
|
|
INDICATIONS:
|
|
|
|
SIDE EFFECTS:
|
|
confusion |
|
eye problems, including dry eyes |
|
eye pain and/or discomfort |
|
fluid imbalance |
|
mood or mental changes, including agitation |
|
hallucinations |
|
panic disorders |
|
restlessness |
|
taste perversion |
|
Chest pain, severe |
|
heaviness, tightness, or pressure in chest, throat, and/or neck |
|
paresthesias |
|
Arrythmias |
|
bradycardia |
|
convulsions |
|
decreased blood pressure |
|
increased blood pressure |
|
Dizziness |
|
drowsiness |
|
malaise |
|
nausea and/or vomiting |
|
Anxiety |
|
arthralgia |
|
blurred vision |
|
chills and/or fever |
|
constipation |
|
diarrhea |
|
gastroenteritis |
|
increased thirst |
|
muscle or joint stiffness, tightness, or rigidity |
|
muscle pain or spasms |
|
palpitations |
|
polyuria |
|
pruritus |
|
sleep disorders |
|
skin rash |
|
stomach discomfort and/or pain |
|
syncope |
|
tremors |
|
Acne |
|
anemia |
|
bone or skeletal pain |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
>> Cerebrovascular accident |
|
>> Coronary artery disease, predisposition to |
|
>> Hepatic function impairment, severe |
|
>> Renal function impairment, severe |
|
>> Hypersensitivity to naratriptan |
|
>> Hypertension, controlled |
|
|
ADULT DOSE:
|
|
Antimigraine agent-
Oral, 1 or 2.5 mg (base) as a single dose. If necessary, additional doses may be taken at intervals of at least four hours .
A starting dose of less than 2.5 mg is recommended for patients with mild to moderate hepatic or renal impairment . |
|
MAXIMUM ADULT DOSE:
|
|
5 mg in twenty-four hours .
2.5 mg in patients with mild or moderate hepatic or renal impairment .
|
|
PEDIATRIC DOSE:
|
|
Safety and efficacy have not been established in children up to 18 years of age .
|
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
Use is not recommended .
|
|
|
|
|
|